抗凝血酵素市场－全球产业规模、份额、趋势、机会、预测：按应用、原料、类型、地区和竞争格局划分，2021-2031年

全球抗凝血酶市场预计将从 2025 年的 7.9311 亿美元成长到 2031 年的 10.8243 亿美元，复合年增长率为 5.32%。

抗凝血酶是一种在肝臟中产生的重要糖蛋白，它透过中和凝血系统中的丝胺酸蛋白酶（如凝血酶和Xa因子）发挥主要的天然抗凝血作用。市场成长的主要驱动因素包括遗传性抗凝血酶缺乏症诊断准确性的提高，以及有效抗凝血治疗在心肺体外迴圈等复杂外科手术中日益重要的作用。标准治疗的限制凸显了开发专用治疗方法的紧迫性。根据国际血栓与止血学会2024年发布的註册数据，58.6%的遗传性抗凝血酶缺乏症患者儘管接受了常规抗凝血治疗，但仍出现血栓症復发，这凸显了临床上对专用抗凝血酶替代产品的需求。

然而，血浆衍生疗法的高昂成本和有限的供应量阻碍了市场扩张，并限制了预算紧张的医疗体系的可及性。抗凝血酶的生产严重依赖人类血浆，而这个过程又受到供体数量和严格安全通讯协定的极大限制。这种对波动性生物原料的依赖造成了供应链的脆弱性，推高了生产成本，最终限制了其在发展中地区的市场渗透。在这些地区，由于财政拮据，医疗机构不得不依赖其他价格较低廉的标准抗凝血剂。

市场驱动因素

全球静脉血栓栓塞症(VTE) 和凝血障碍发生率的上升是推动市场成长的主要催化剂，因此亟需针对高风险族群采取强有力的治疗性介入。血栓事件的全球性增加，尤其是在遗传性抗凝血酶缺乏症患者以及接受复杂手术且标准肝素疗效不佳的患者中，正推动对特殊替代疗法的需求激增。这种不断增长的临床需求在主要企业的财务表现中得到了清晰的体现。例如，Griffols 公司在 2025 年 2 月公布，其生物製药部门 2024 年第四季的销售额成长了 15.1%，这显然与全球对血浆蛋白的强劲需求密切相关。

同时，血浆来源抗凝血酶浓缩物的供应日益稳定，以往的供应链问题得到解决，确保患者能可靠地获得所需药物。市场稳定取决于人血浆的高效收集和分离，主要行业参与者正在优化营运并扩大相关领域的产能。 Kedrion BioPharma 2025 年 4 月公布的年销售额为 15.78 亿欧元，较去年同期成长 10%，主要得益于其血浆衍生产品组合的成长。严格的安全标准保障了永续的供应，从而支撑了这一成长。 2025 年 2 月，血浆蛋白治疗协会指出，捐血中不利事件的发生率仅为 0.16%，并确认了维持抗凝血酵素生产所需基本捐血者族群的安全通讯协定。

市场挑战

全球抗凝血酶市场面临的主要障碍在于其对人类血浆分馏的依赖。血浆衍生疗法依赖有限的生物资源，难以快速扩大规模以满足日益增长的临床需求。此外，该行业对特定采集区域的依赖进一步加剧了这一限制，导致供应链脆弱性。根据血浆蛋白治疗协会 (PPTA) 2025 年的数据，全球超过 63% 的用于生产的血浆将来自北美，凸显了原料的严重地域集中。因此，这个主要供应区域的任何中断都将立即影响全球供应，威胁产品供应的稳定性并限制商机。

此外，为确保病毒安全性和产品纯度，复杂的生产流程会产生高昂的营运成本。这些成本导致价格上涨，限制了产品在对成本敏感的医疗保健市场的普及。在预算有限的发展中地区，医疗机构往往选择成本较低的特异性抗凝血剂，而非专业的抗凝血酶疗法。这种经济壁垒直接阻碍了市场渗透，抑制了抗凝血酶疗法在新兴经济体的广泛应用，从而限制了该市场的整体全球成长潜力。

市场趋势

体外膜氧合（ECMO）通讯协定的日益普及正在改变市场需求。临床医师经常选择抗凝血酵素替代疗法来治疗严重患者的肝素抗性。在长时间的体外循环支持过程中，天然抗凝血酵素会被迅速消耗，因此外源性补充对于维持循环通畅性和预防危险的血栓症形成至关重要，而标准抗凝血疗法往往不足以达到此目的。这种与高阶生命支持的整合使得治疗性抗凝血酶的消耗量与机械循环支持装置的使用量之间形成了直接关联。体外生命支持系统（ELSO）报告称，到2025年4月，全球累积註册量将达到245,291台，显示对可靠的辅助抗凝血治疗的需求呈强劲上升趋势。

同时，市场正拓展其临床应用，将抗凝血酶应用于败血症和创伤的治疗。抗凝血酵素被定位为一种双效疗法，利用其抗发炎特性来控制脓毒性败血性休克的凝血障碍。相关人员正积极寻求扩大其在瀰漫性血管内凝血（DIC）治疗中的适应症，旨在将这种生物製药从一种小众孤儿药提升为主流重症监护疗法。这项策略旨在满足巨大的未满足需求。正如全球败血症联盟在2025年7月指出的那样，败血症约占全球死亡人数的五分之一，这意味着庞大的患者群体，为血浆衍生疗法的市场拓展提供了巨大的潜力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球抗凝血酵素市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按应用领域（治疗、诊断、研究、其他）
  • 来源（人类来源、基因改造山羊乳来源、其他）
  • 依类型（抗凝血剂、抗血小板药物、溶栓药物）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美抗凝血酵素市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲抗凝血酵素市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗凝血酵素市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲抗凝血酵素市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲抗凝血酵素市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球抗凝血酵素市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Grifols, SA
• Takeda Pharmaceutical Company Limited
• Octapharma Brasil Ltda.
• LFB USA, Inc.
• Endpoint Health, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• BioCare, Inc.
• F. Hoffmann-La Roche Ltd
• Kedrion SpA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Antithrombin Market is projected to expand from USD 793.11 Million in 2025 to USD 1082.43 Million by 2031, registering a CAGR of 5.32%. As a vital liver-produced glycoprotein, antithrombin acts as a key natural anticoagulant by neutralizing serine proteases like thrombin and Factor Xa within the coagulation system. Market growth is largely driven by improved diagnosis of hereditary antithrombin deficiency and the critical need for effective anticoagulation during complex surgical procedures, such as cardiopulmonary bypass operations. The urgency for specialized therapies is highlighted by the limitations of standard treatments; registry data cited by the International Society on Thrombosis and Haemostasis in 2024 revealed that recurrent thrombosis affected 58.6% of patients with hereditary deficiency despite conventional anticoagulation, emphasizing the clinical necessity for dedicated antithrombin replacement products.

However, market expansion is hindered by the significant costs and restricted availability associated with plasma-derived therapeutics, which limit access within budget-constrained healthcare systems. Antithrombin production depends heavily on human plasma fractionation, a process strictly bound by donor availability and rigorous safety protocols. This reliance on a variable biological raw material introduces supply chain vulnerabilities and drives up manufacturing costs, ultimately curbing market penetration in developing regions where financial constraints often force healthcare providers to rely on alternative, less expensive standard-of-care anticoagulants.

Market Driver

The increasing global incidence of Venous Thromboembolism (VTE) and coagulation disorders acts as a major catalyst for market growth, necessitating strong therapeutic interventions for high-risk populations. With thrombotic events rising worldwide-especially among those with hereditary antithrombin deficiency or undergoing complex surgeries where standard heparin is inadequate-the demand for specialized replacement therapies has surged. This elevated clinical need is evident in the financial results of leading manufacturers; for instance, Grifols reported in February 2025 that its Biopharma unit saw a 15.1% revenue increase in the fourth quarter of 2024, a performance the company explicitly linked to robust global demand for plasma proteins.

Concurrently, the market is benefiting from the improved availability of plasma-derived antithrombin concentrates, which is addressing past supply chain issues and enabling reliable patient access. Market stability depends on efficient human plasma collection and fractionation, areas where key industry players have optimized operations and expanded capacity. Reflecting this progress, Kedrion Biopharma reported in April 2025 a fiscal year turnover of 1.578 billion Euros-a 10% increase driven by its plasma-derived portfolio. This growth is supported by strict safety standards that ensure a sustainable supply; the Plasma Protein Therapeutics Association noted in February 2025 that adverse events occur in only 0.16% of donations, confirming the safety protocols necessary to maintain the donor base essential for antithrombin production.

Market Challenge

A significant obstacle to the Global Antithrombin Market is its reliance on human plasma fractionation, as plasma-derived therapies depend on a finite biological resource that cannot be rapidly scaled to match rising clinical needs. This limitation is exacerbated by the industry's dependence on specific collection regions, leading to supply chain fragility. According to 2025 data from the Plasma Protein Therapeutics Association, North America provided over 63% of the global plasma utilized for manufacturing, highlighting a severe geographic concentration of raw material. Consequently, any interruption in this primary source region immediately affects global availability, threatening consistent product delivery and restricting revenue opportunities.

Furthermore, the intricate manufacturing processes necessary to guarantee viral safety and product purity involve high operational costs. These expenses translate into elevated pricing structures that restrict product accessibility in cost-sensitive healthcare markets. In developing regions with limited budgets, medical providers frequently opt for lower-cost, non-specific anticoagulants instead of specialized antithrombin treatments. This economic barrier directly hinders market penetration and blocks the widespread adoption of antithrombin therapies in emerging economies, effectively limiting the market's overall global growth potential.

Market Trends

The increasing use of Extracorporeal Membrane Oxygenation (ECMO) protocols is altering market demand, as clinicians frequently turn to antithrombin supplementation to manage heparin resistance in critically ill patients. Standard anticoagulation often proves insufficient during prolonged extracorporeal support because natural antithrombin is rapidly consumed, requiring exogenous replacement to maintain circuit patency and prevent dangerous thrombosis. This integration into advanced life support creates a direct link between therapeutic consumption and the rising use of mechanical circulatory support; the Extracorporeal Life Support Organization reported in April 2025 that cumulative global registry volume hit 245,291 ECMO runs, demonstrating a strong upward trend that requires reliable adjunct anticoagulation.

Simultaneously, the market is expanding its clinical scope into sepsis and trauma care, positioning antithrombin as a dual-action therapy that utilizes its anti-inflammatory properties to manage coagulopathy in septic shock. Industry stakeholders are actively seeking label expansions to treat disseminated intravascular coagulation, aiming to elevate the biologic from a niche orphan drug to a mainstream critical care treatment. This strategy addresses a massive unmet medical need; as highlighted by the Global Sepsis Alliance in July 2025, sepsis causes approximately one in five deaths worldwide, representing a vast patient population that could significantly increase the addressable market for plasma-derived therapies.

Key Market Players

• Grifols, S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma Brasil Ltda.
• LFB USA, Inc.
• Endpoint Health, Inc.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc
• BioCare, Inc.
• F. Hoffmann-La Roche Ltd
• Kedrion S.p.A

Report Scope

In this report, the Global Antithrombin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antithrombin Market, By Usage

• Therapeutics
• Diagnostics
• Research
• Others

Antithrombin Market, By Source

• Human
• Recombinant Goat Milk
• Others

Antithrombin Market, By Type

• Anticoagulant
• Antiplatelet
• Thrombolytic Drugs

Antithrombin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antithrombin Market.

Available Customizations:

Global Antithrombin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antithrombin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Usage (Therapeutics, Diagnostics, Research, Others)
  • 5.2.2. By Source (Human, Recombinant Goat Milk, Others)
  • 5.2.3. By Type (Anticoagulant, Antiplatelet, Thrombolytic Drugs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Antithrombin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Usage
  • 6.2.2. By Source
  • 6.2.3. By Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antithrombin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Usage
      • 6.3.1.2.2. By Source
      • 6.3.1.2.3. By Type
  • 6.3.2. Canada Antithrombin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Usage
      • 6.3.2.2.2. By Source
      • 6.3.2.2.3. By Type
  • 6.3.3. Mexico Antithrombin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Usage
      • 6.3.3.2.2. By Source
      • 6.3.3.2.3. By Type

7. Europe Antithrombin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Usage
  • 7.2.2. By Source
  • 7.2.3. By Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antithrombin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Usage
      • 7.3.1.2.2. By Source
      • 7.3.1.2.3. By Type
  • 7.3.2. France Antithrombin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Usage
      • 7.3.2.2.2. By Source
      • 7.3.2.2.3. By Type
  • 7.3.3. United Kingdom Antithrombin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Usage
      • 7.3.3.2.2. By Source
      • 7.3.3.2.3. By Type
  • 7.3.4. Italy Antithrombin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Usage
      • 7.3.4.2.2. By Source
      • 7.3.4.2.3. By Type
  • 7.3.5. Spain Antithrombin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Usage
      • 7.3.5.2.2. By Source
      • 7.3.5.2.3. By Type

8. Asia Pacific Antithrombin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Usage
  • 8.2.2. By Source
  • 8.2.3. By Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Antithrombin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Usage
      • 8.3.1.2.2. By Source
      • 8.3.1.2.3. By Type
  • 8.3.2. India Antithrombin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Usage
      • 8.3.2.2.2. By Source
      • 8.3.2.2.3. By Type
  • 8.3.3. Japan Antithrombin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Usage
      • 8.3.3.2.2. By Source
      • 8.3.3.2.3. By Type
  • 8.3.4. South Korea Antithrombin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Usage
      • 8.3.4.2.2. By Source
      • 8.3.4.2.3. By Type
  • 8.3.5. Australia Antithrombin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Usage
      • 8.3.5.2.2. By Source
      • 8.3.5.2.3. By Type

9. Middle East & Africa Antithrombin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Usage
  • 9.2.2. By Source
  • 9.2.3. By Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Antithrombin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Usage
      • 9.3.1.2.2. By Source
      • 9.3.1.2.3. By Type
  • 9.3.2. UAE Antithrombin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Usage
      • 9.3.2.2.2. By Source
      • 9.3.2.2.3. By Type
  • 9.3.3. South Africa Antithrombin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Usage
      • 9.3.3.2.2. By Source
      • 9.3.3.2.3. By Type

10. South America Antithrombin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Usage
  • 10.2.2. By Source
  • 10.2.3. By Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Antithrombin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Usage
      • 10.3.1.2.2. By Source
      • 10.3.1.2.3. By Type
  • 10.3.2. Colombia Antithrombin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Usage
      • 10.3.2.2.2. By Source
      • 10.3.2.2.3. By Type
  • 10.3.3. Argentina Antithrombin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Usage
      • 10.3.3.2.2. By Source
      • 10.3.3.2.3. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Antithrombin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Grifols, S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Takeda Pharmaceutical Company Limited
• 15.3. Octapharma Brasil Ltda.
• 15.4. LFB USA, Inc.
• 15.5. Endpoint Health, Inc.
• 15.6. Siemens Healthineers AG
• 15.7. Thermo Fisher Scientific Inc
• 15.8. BioCare, Inc.
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. Kedrion S.p.A

16. Strategic Recommendations

17. About Us & Disclaimer